Nakazato Hidetsugu, Takeshima Hideyuki, Kishino Takayoshi, Kubo Emi, Hattori Naoko, Nakajima Takeshi, Yamashita Satoshi, Igaki Hiroyasu, Tachimori Yuji, Kuniyoshi Yukio, Ushijima Toshikazu
Division of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan.
Esophageal Surgery Division, National Cancer Center Hospital, Tokyo, Japan.
PLoS One. 2016 Jan 26;11(1):e0147372. doi: 10.1371/journal.pone.0147372. eCollection 2016.
The SWI/SNF chromatin remodeling complex is frequently inactivated by somatic mutations of its various components in various types of cancers, and also by aberrant DNA methylation. However, its somatic mutations and aberrant methylation in esophageal squamous cell carcinomas (ESCCs) have not been fully analyzed. In this study, we aimed to clarify in ESCC, what components of the SWI/SNF complex have somatic mutations and aberrant methylation, and when somatic mutations of the SWI/SNF complex occur. Deep sequencing of components of the SWI/SNF complex using a bench-top next generation sequencer revealed that eight of 92 ESCCs (8.7%) had 11 somatic mutations of 7 genes, ARID1A, ARID2, ATRX, PBRM1, SMARCA4, SMARCAL1, and SMARCC1. The SMARCA4 mutations were located in the Forkhead (85Ser>Leu) and SNF2 family N-terminal (882Glu>Lys) domains. The PBRM1 mutations were located in a bromodomain (80Asn>Ser) and an HMG-box domain (1,377Glu>Lys). For most mutations, their mutant allele frequency was 31-77% (mean 61%) of the fraction of cancer cells in the same samples, indicating that most of the cancer cells in individual ESCC samples had the SWI/SNF mutations on one allele, when present. In addition, a BeadChip array analysis revealed that a component of the SWI/SNF complex, ACTL6B, had aberrant methylation at its promoter CpG island in 18 of 52 ESCCs (34.6%). These results showed that genetic and epigenetic alterations of the SWI/SNF complex are present in ESCCs, and suggested that genetic alterations are induced at an early stage of esophageal squamous cell carcinogenesis.
SWI/SNF染色质重塑复合体在各类癌症中常因各种组分的体细胞突变以及异常的DNA甲基化而失活。然而,其在食管鳞状细胞癌(ESCC)中的体细胞突变和异常甲基化情况尚未得到充分分析。在本研究中,我们旨在阐明在ESCC中,SWI/SNF复合体的哪些组分存在体细胞突变和异常甲基化,以及SWI/SNF复合体的体细胞突变何时发生。使用台式下一代测序仪对SWI/SNF复合体的组分进行深度测序发现,92例ESCC中有8例(8.7%)存在7个基因(ARID1A、ARID2、ATRX、PBRM1、SMARCA4、SMARCAL1和SMARCC1)的11种体细胞突变。SMARCA4突变位于叉头结构域(85Ser>Leu)和SNF2家族N端结构域(882Glu>Lys)。PBRM1突变位于一个溴结构域(80Asn>Ser)和一个HMG盒结构域(1377Glu>Lys)。对于大多数突变,其突变等位基因频率为同一样本中癌细胞比例的31% - 77%(平均61%),这表明当存在时,单个ESCC样本中的大多数癌细胞在一个等位基因上存在SWI/SNF突变。此外,BeadChip阵列分析显示,SWI/SNF复合体的一个组分ACTL6B在52例ESCC中的18例(34.6%)的启动子CpG岛处存在异常甲基化。这些结果表明ESCC中存在SWI/SNF复合体的遗传和表观遗传改变,并提示遗传改变在食管鳞状细胞癌发生的早期阶段就被诱导。